IL37 and familial dilated cardiomyopathy: In addition, the cardiac hypertrophic features in DCM mice including increased heart weights, enlarged cardiomyocytes and upregulated myocardial hypertrophic markers were significantly inhibited by IL-37 administration, as evidenced by decreased heart cross-sectional area, reduced cardiomyocyte size and downregulated mRNA levels of CTGF, ANP and BNP (Fig. 2C-F).